FindTrial
Sign In

A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vitiligo

Status
Withdrawn
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-515642-17-00
Enrollment
74
Registered
2024-10-09
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-segmental vitiligo

Brief summary

Proportion of subjects achieving VASI-50 (defined as at least 50% improvement in VASI from baseline) at Week 32. - Percent change from baseline in VASI, facial-VASI, vitiligo extent score (VES), and self-assessment VES (SA-VES) and absolute change from baseline in VASI at designated time points - Change from baseline in vitiligo specific quality of life (VitiQoL) and dermatology quality life index (DLQI) at designated time points.

Interventions

DRUGPioglitazone Morningside 15mg Tablets

Sponsors

I.F.O. Istituti Fisioterapici Ospitalieri
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Proportion of subjects achieving VASI-50 (defined as at least 50% improvement in VASI from baseline) at Week 32. - Percent change from baseline in VASI, facial-VASI, vitiligo extent score (VES), and self-assessment VES (SA-VES) and absolute change from baseline in VASI at designated time points - Change from baseline in vitiligo specific quality of life (VitiQoL) and dermatology quality life index (DLQI) at designated time points.—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026